The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwMyeloma 2015 | Novel kinase targets as emerging therapies for multiple myeloma
At the Myeloma 2015 meeting, Dr Sergio Giralt (Memorial Sloan-Kettering Cancer Center, New York, NY) chairs a discussion with Prof Faith Davies (The University of Arkansas for Medical Sciences (UAMS), Little Rock, AR) and Prof Shaji Kumar (Mayo Clinic, Rochester, MN) on their studies of novel kinase inhibitors in clinical development for the treatment of multiple myeloma. They focus on inhibitors of mitogen-activated protein kinase kinase (MEK) and Provirus Integration site for Moloney leukemia (PIM) kinases.
